MAP3K8/TPL-2/COT is a potential predictive marker for MEK inhibitor treatment in high-grade serous ovarian carcinomas

Whole–genome characterization of chemoresistant ovarian cancer

(2015) Ann-Marie Patch et al.   NATURE

Systematic transcriptome analysis reveals tumor-specific isoforms for ovarian cancer diagnosis and therapy

(2015) Christian L. Barrett et al.   PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA

Inhibition of autophagy as a new means of improving chemotherapy efficiency in high-LC3B triple-negative breast cancers

(2014) Sylvain Lefort et al.   Autophagy

MEK1/2 inhibitors in the treatment of gynecologic malignancies

(2014) Caela R. Miller et al.   GYNECOLOGIC ONCOLOGY

Prognostic and Therapeutic Relevance of Molecular Subtypes in High-Grade Serous Ovarian Cancer

(2014) Gottfried E. Konecny et al.   JNCI-Journal of the National Cancer Institute

Molecular correlates of platinum response in human high-grade serous ovarian cancer patient-derived xenografts

(2014) Monique D. Topp et al.   Molecular Oncology

Ovarian Cancer Cell Line Panel (OCCP): Clinical Importance of In Vitro Morphological Subtypes

(2014) Corine M. Beaufort et al.   PLoS One

A survival analysis comparing women with ovarian low-grade serous carcinoma to those with high-grade histology

(2014) Ming Chen et al.   OncoTargets and Therapy

B-Raf mutation: A key player in molecular biology of cancer

(2013) M.A. Rahman et al.   EXPERIMENTAL AND MOLECULAR PATHOLOGY

Ovarian cancer emerging subtypes: Role of oxidative stress and fibrosis in tumour development and response to treatment

(2013) L. Batista et al.   INTERNATIONAL JOURNAL OF BIOCHEMISTRY & CELL BIOLOGY

Overexpression of CK20, MAP3K8 and EIF5A correlates with poor prognosis in early-onset colorectal cancer patients

(2013) Berrin Tunca et al.   JOURNAL OF CANCER RESEARCH AND CLINICAL ONCOLOGY

KRASMutation: Should We Test for It, and Does It Matter?

(2013) Patrick J. Roberts et al.   JOURNAL OF CLINICAL ONCOLOGY

Tpl2 Kinase Impacts Tumor Growth and Metastasis of Clear Cell Renal Cell Carcinoma

(2013) H. W. Lee et al.   MOLECULAR CANCER RESEARCH

TPL2 kinase is a suppressor of lung carcinogenesis

(2013) K. Gkirtzimanaki et al.   PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA

Evaluating cell lines as tumour models by comparison of genomic profiles

(2013) Silvia Domcke et al.   Nature Communications

Ploidy and Large-Scale Genomic Instability Consistently Identify Basal-like Breast Carcinomas with BRCA1/2 Inactivation

(2012) T. Popova et al.   CANCER RESEARCH

IκB kinase regulation of the TPL-2/ERK MAPK pathway

(2012) Thorsten Gantke et al.   IMMUNOLOGICAL REVIEWS

Selumetinib in women with recurrent low-grade serous carcinoma of the ovary or peritoneum: an open-label, single-arm, phase 2 study

(2012) John Farley et al.   LANCET ONCOLOGY

I B Kinase 2 Regulates TPL-2 Activation of Extracellular Signal-Regulated Kinases 1 and 2 by Direct Phosphorylation of TPL-2 Serine 400

(2012) K. Roget et al.   MOLECULAR AND CELLULAR BIOLOGY

Combined BRAF and MEK Inhibition in Melanoma with BRAF V600 Mutations

(2012) Keith T. Flaherty et al.   NEW ENGLAND JOURNAL OF MEDICINE

Angiogenic mRNA and microRNA Gene Expression Signature Predicts a Novel Subtype of Serous Ovarian Cancer

(2012) Stefan Bentink et al.   PLoS One

Regulation and function of the RSK family of protein kinases

(2011) Yves Romeo et al.   BIOCHEMICAL JOURNAL

Tpl2 kinase signal transduction in inflammation and cancer

(2011) Maria Vougioukalaki et al.   CANCER LETTERS

Getting Around PLX4032: Studies Turn Up Unusual Mechanisms of Resistance to Melanoma Drug

(2011) R. S. Tuma   JNCI-Journal of the National Cancer Institute

Integrated genomic analyses of ovarian carcinoma

(2011) D. Bell et al.   NATURE

miR-141 and miR-200a act on ovarian tumorigenesis by controlling oxidative stress response

(2011) Bogdan Mateescu et al.   NATURE MEDICINE

Defining MAP3 kinases required for MDA-MB-231 cell tumor growth and metastasis

(2011) M R Cronan et al.   ONCOGENE

TPL2/COT/MAP3K8 (TPL2) Activation Promotes Androgen Depletion-Independent (ADI) Prostate Cancer Growth

(2011) Joseph H. Jeong et al.   PLoS One

Regulation and function of TPL-2, an IκB kinase-regulated MAP kinase kinase kinase

(2010) Thorsten Gantke et al.   CELL RESEARCH

Oxidative stress promotes myofibroblast differentiation and tumour spreading

(2010) Aurore Toullec et al.   EMBO Molecular Medicine

Cellular functions of FAK kinases: insight into molecular mechanisms and novel functions

(2010) M. D. Schaller   JOURNAL OF CELL SCIENCE

Oral poly(ADP-ribose) polymerase inhibitor olaparib in patients with BRCA1 or BRCA2 mutations and recurrent ovarian cancer: a proof-of-concept trial

(2010) M William Audeh et al.   LANCET

Genome remodelling in a basal-like breast cancer metastasis and xenograft

(2010) Li Ding et al.   NATURE

COT drives resistance to RAF inhibition through MAP kinase pathway reactivation

(2010) Cory M. Johannessen et al.   NATURE

TPL-2-Mediated Activation of MAPK Downstream of TLR4 Signaling Is Coupled to Arginine Availability

(2010) V. Mieulet et al.   Science Signaling

Tpl2 Is a Key Mediator of Arsenite-Induced Signal Transduction

(2009) K. M. Lee et al.   CANCER RESEARCH

RSK Is a Principal Effector of the RAS-ERK Pathway for Eliciting a Coordinate Promotile/Invasive Gene Program and Phenotype in Epithelial Cells

(2009) Ulrik Doehn et al.   MOLECULAR CELL

Novel Molecular Subtypes of Serous and Endometrioid Ovarian Cancer Linked to Clinical Outcome

(2008) R. W. Tothill et al.   CLINICAL CANCER RESEARCH